Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 234851, 10 pages
http://dx.doi.org/10.1155/2015/234851
Review Article

HER2 Status in Premalignant, Early, and Advanced Neoplastic Lesions of the Stomach

1Department of Human Pathology “Gaetano Barresi”, Section of Anatomic Pathology, Azienda Ospedaliera Universitaria “Gaetano Martino, University of Messina,” Via Consolare Valeria 1, 98125 Messina, Italy
2Department of Pediatrics, Gynecology and Microbiology Sciences, Azienda Ospedaliera Universitaria “Gaetano Martino, University of Messina,” Via Consolare Valeria 1, 98125 Messina, Italy

Received 5 June 2015; Accepted 30 July 2015

Academic Editor: Omeed Moaven

Copyright © 2015 A. Ieni et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. De Angelis, M. Sant, M. P. Coleman et al., “Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE—5-a population-based study,” The Lancet Oncology, vol. 15, no. 1, pp. 23–34, 2014. View at Google Scholar
  2. R. A. Caruso, E. Irato, G. Branca, G. Finocchiaro, F. Fedele, and A. Arnese, “Gastric adenocarcinoma incidence in the province of Messina (Insular Italy): a cancer registry study,” Oncology Letters, vol. 7, no. 3, pp. 861–865, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Ieni, G. Branca, A. Parisi et al., “Neutrophil-rich gastric carcinoma in the integrated cancer registry of eastern Sicily, Italy,” Anticancer Research, vol. 35, no. 1, pp. 487–492, 2015. View at Google Scholar · View at Scopus
  4. L. Rigoli and R. A. Caruso, “Mitochondrial DNA alterations in the progression of gastric carcinomas: unexplored issues and future research needs,” World Journal of Gastroenterology, vol. 20, no. 43, pp. 16159–16166, 2014. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Barchielli, A. Amorosi, D. Balzi, E. Crocetti, and G. Nesi, “Long-term prognosis of gastric cancer in a European country: a population-based study in Florence (Italy). 10-year survival of cases diagnosed in 1985–1987,” European Journal of Cancer, vol. 37, no. 13, pp. 1674–1680, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Inghelmann, E. Grande, S. Francisci et al., “Regional estimates of stomach cancer burden in Italy,” Tumori, vol. 93, no. 4, pp. 367–373, 2007. View at Google Scholar · View at Scopus
  7. M. Castaing, F. Bella, and C. Buzzoni, “Incidence of stomach cancer is decreasing faster in the Centre-North of Italy,” Epidemiologia & Prevenzione, vol. 36, no. 2, p. 129, 2012. View at Google Scholar
  8. M. Vauhkonen, H. Vauhkonen, and P. Sipponen, “Pathology and molecular biology of gastric cancer,” Best Practice and Research: Clinical Gastroenterology, vol. 20, no. 4, pp. 651–674, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. P. Correa, C. Cuello, and W. Haenszel, “The pathogenesis of gastric carcinoma—epidemiologic pathology of precursor lesions,” Leber Magen Darm, vol. 6, no. 2, pp. 72–79, 1976. View at Google Scholar · View at Scopus
  10. C. Cuello, P. Correa, W. Haenszel et al., “Gastric cancer in Colombia. I. Cancer risk and suspect environmental agents,” Journal of the National Cancer Institute, vol. 57, no. 5, pp. 1015–1020, 1976. View at Google Scholar · View at Scopus
  11. W. Haenszel, P. Correa, C. Cuello et al., “Gastric cancer in Colombia. II. Case-control epidemiologic study of precursor lesions,” Journal of the National Cancer Institute, vol. 57, no. 5, pp. 1021–1026, 1976. View at Google Scholar · View at Scopus
  12. P. Correa, W. Haenszel, C. Cuello et al., “Gastric precancerous process in a high risk population: cohort follow-up,” Cancer Research, vol. 50, no. 15, pp. 4737–4740, 1990. View at Google Scholar · View at Scopus
  13. H. Ohata, S. Kitauchi, N. Yoshimura et al., “Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer,” International Journal of Cancer, vol. 109, no. 1, pp. 138–143, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. P. Correa, “Antioxidant vitamin supplementation and control of gastric cancer,” Nature Clinical Practice Oncology, vol. 4, no. 8, pp. 452–453, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Zheng, L. Wang, J. Ajani, and K. Xie, “Molecular basis of gastric cancer development and progression,” Gastric Cancer, vol. 7, no. 2, pp. 61–77, 2004. View at Google Scholar · View at Scopus
  16. M. H. McLean and E. M. El-Omar, “Genetics of gastric cancer,” Nature Reviews Gastroenterology and Hepatology, vol. 11, no. 11, pp. 664–674, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. C. Lengauer, K. W. Kinzler, and B. Vogelstein, “Genetic instabilities in human cancers,” Nature, vol. 396, no. 6762, pp. 643–649, 1998. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Hudler, “Genetic aspects of gastric cancer instability,” The Scientific World Journal, vol. 2012, Article ID 761909, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. Cancer Genome Atlas Research Network, “Comprehensive molecular characterization of gastric adenocarcinoma,” Nature, vol. 513, no. 7517, pp. 202–209, 2014. View at Google Scholar
  20. J. Czyzewska, K. Guzinska-Ustymowicz, and A. Kemona, “Correlation of c-erbB-2, EGF and EGFR expression with postoperative survival of patients with advanced carcinoma of the stomach,” Folia Histochemica et Cytobiologica, vol. 47, no. 4, pp. 653–661, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. J. Slamon, B. Leyland-Jones, S. Shak et al., “Use of chemotherapy plus a monoclonal antibody against her2 for metastatic breast cancer that overexpresses HER2,” The New England Journal of Medicine, vol. 344, no. 11, pp. 783–792, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. J. Bang, E. Van Cutsem, A. Feyereislova et al., “Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial,” The Lancet, vol. 376, no. 9742, pp. 687–697, 2010. View at Google Scholar
  23. R. Nishimura, K.-I. Mukaisho, H. Yamamoto et al., “Precursor-derived versus de-novo carcinogenesis depends on lineage-specific mucin phenotypes of intramucosal gland-forming gastric neoplasms,” Histopathology, vol. 63, no. 5, pp. 616–629, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. R. Kushima, M. Vieth, F. Borchard, M. Stolte, K.-I. Mukaisho, and T. Hattori, “Gastric-type well-differentiated adenocarcinoma and pyloric gland adenoma of the stomach,” Gastric Cancer, vol. 9, no. 3, pp. 177–184, 2006. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Carl-McGrath, M. Ebert, and C. Röcken, “Gastric adenocarcinoma: epidemiology, pathology and pathogenesis,” Cancer Therapy, vol. 5, no. 2, pp. 877–894, 2007. View at Google Scholar
  26. M. Rugge, P. Correa, M. F. Dixon et al., “Gastric dysplasia: the Padova International classification,” The American Journal of Surgical Pathology, vol. 24, no. 2, pp. 167–176, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. R. J. Schlemper, R. H. Riddell, Y. Kato et al., “The Vienna classification of gastrointestinal epithelial neoplasia,” Gut, vol. 47, no. 2, pp. 251–255, 2000. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Rugge, M. de Boni, G. Pennelli et al., “Gastritis OLGA-staging and gastric cancer risk: a twelve-year clinico-pathological follow-up study,” Alimentary Pharmacology and Therapeutics, vol. 31, no. 10, pp. 1104–1111, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. M. Rugge, F. Farinati, R. Baffa et al., “Gastric epithelial dysplasia in the natural history of gastric cancer: a multicenter prospective follow-up study. Interdisciplinary Group on Gastric Epithelial Dysplasia,” Gastroenterology, vol. 107, no. 5, pp. 1288–1296, 1994. View at Publisher · View at Google Scholar · View at Scopus
  30. M. Cassaro, M. Rugge, C. Tieppo et al., “Indefinite for non-invasive neoplasia lesions in gastric intestinal metaplasia: the immunophenotype,” Journal of Clinical Pathology, vol. 60, no. 6, pp. 615–621, 2007. View at Publisher · View at Google Scholar · View at Scopus
  31. P. Correa, M. B. Piazuelo, and K. T. Wilson, “Pathology of gastric intestinal metaplasia: clinical implications,” The American Journal of Gastroenterology, vol. 105, no. 3, pp. 493–498, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. X. Xu, L. Feng, Y. Liu et al., “Differential gene expression profiling of gastric intraepithelial neoplasia and early-stage adenocarcinoma,” World Journal of Gastroenterology, vol. 20, no. 47, pp. 17883–17893, 2014. View at Publisher · View at Google Scholar · View at Scopus
  33. G. Testino, “Gastric precancerous changes: carcinogenesis, clinical behaviour immunophenotype study and surveillance,” Panminerva Medica, vol. 48, no. 2, pp. 109–118, 2006. View at Google Scholar · View at Scopus
  34. L.-L. Lin, H.-C. Huang, and H.-F. Juan, “Discovery of biomarkers for gastric cancer: a proteomics approach,” Journal of Proteomics, vol. 75, no. 11, pp. 3081–3097, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. Z.-H. Zheng, X.-J. Sun, M.-C. Ma, D.-M. Hao, Y.-H. Liu, and K.-L. Sun, “Studies of promoter methylation status and protein expression of E-cadherin gene in associated progression stages of gastric cancer,” Yichuan Xuebao, vol. 30, no. 2, pp. 103–108, 2003. View at Google Scholar · View at Scopus
  36. E. Rossi, S. Grisanti, V. Villanacci et al., “HER-2 overexpression/amplification in Barrett's oesophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study,” Journal of Cellular and Molecular Medicine, vol. 13, no. 9, pp. 3826–3833, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. D. T. Merrick, J. Kittelson, R. Winterhalder et al., “Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer,” Clinical Cancer Research, vol. 12, no. 7, part 1, pp. 2281–2288, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. M. J. van de Vijver, J. L. Peterse, W. J. Mooi et al., “Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer,” The New England Journal of Medicine, vol. 319, no. 19, pp. 1239–1245, 1988. View at Google Scholar · View at Scopus
  39. R. F. Lodato, H. C. Maguire Jr., M. I. Greene, D. B. Weiner, and V. A. LiVolsi, “Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast,” Modern Pathology, vol. 3, no. 4, pp. 449–454, 1990. View at Google Scholar · View at Scopus
  40. M. Van Bockstal, K. Lambein, H. Denys et al., “Histopathological characterization of ductal carcinoma in situ (DCIS) of the breast according to HER2 amplification status and molecular subtype,” Virchows Archiv, vol. 465, no. 3, pp. 275–289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  41. N. Fusco, E. G. Rocco, C. Del Conte et al., “HER2 in gastric cancer: a digital image analysis in pre-neoplastic, primary and metastatic lesions,” Modern Pathology, vol. 26, no. 6, pp. 816–824, 2013. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Fassan, L. Mastracci, F. Grillo et al., “Early HER2 dysregulation in gastric and oesophageal carcinogenesis,” Histopathology, vol. 61, no. 5, pp. 769–776, 2012. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Villanacci, E. Rossi, S. Grisanti et al., “Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach,” Minerva Gastroenterologica e Dietologica, vol. 54, no. 4, pp. 347–353, 2008. View at Google Scholar · View at Scopus
  44. E. Rossi, V. Villanacci, G. Bassotti et al., “TOPOIIalpha and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma,” Histopathology, vol. 57, no. 1, pp. 81–89, 2010. View at Publisher · View at Google Scholar · View at Scopus
  45. Y. Hu, S. Bandla, T. E. Godfrey et al., “HER2 amplification, overexpression and score criteria in esophageal adenocarcinoma,” Modern Pathology, vol. 24, no. 7, pp. 899–907, 2011. View at Publisher · View at Google Scholar · View at Scopus
  46. S. Lee, W. B. de Boer, S. Fermoyle, M. Platten, and M. P. Kumarasinghe, “Human epidermal growth factor receptor 2 testing in gastric carcinoma: issues related to heterogeneity in biopsies and resections,” Histopathology, vol. 59, no. 5, pp. 832–840, 2011. View at Publisher · View at Google Scholar · View at Scopus
  47. A. M. M. F. Nogueira, J. C. Machado, F. Carneiro, C. A. Reis, P. Gött, and M. Sobrinho-Simões, “Patterns of expression of trefoil peptides and mucins in gastric polyps with and without malignant transformation,” Journal of Pathology, vol. 187, no. 5, pp. 541–548, 1999. View at Publisher · View at Google Scholar · View at Scopus
  48. D. Y. Park, A. Srivastava, G. H. Kim et al., “Adenomatous and foveolar gastric dysplasia: distinct patterns of mucin expression and background intestinal metaplasia,” The American Journal of Surgical Pathology, vol. 32, no. 4, pp. 524–533, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. D. Y. Park, A. Srivastava, G. H. Kim et al., “CDX2 expression in the intestinal-type gastric epithelial neoplasia: frequency and significance,” Modern Pathology, vol. 23, no. 1, pp. 54–61, 2010. View at Publisher · View at Google Scholar · View at Scopus
  50. P. Valente, M. Garrido, I. Gullo et al., “Epithelial dysplasia of the stomach with gastric immunophenotype shows features of biological aggressiveness,” Gastric Cancer, 2014. View at Publisher · View at Google Scholar · View at Scopus
  51. J. H. Kang, Y. J. Lim, J. H. Kang et al., “Prevalence of precancerous conditions and gastric cancer based upon the national cancer screening program in Korea for 7 years, single center experience,” Gastroenterology Research and Practice, vol. 2015, Article ID 571965, 5 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  52. B. Hu, N. El Hajj, S. Sittler et al., “Gastric cancer: classification, histology and application of molecular pathology,” Journal of Gastrointestinal Oncology, vol. 3, no. 3, pp. 251–261, 2012. View at Google Scholar
  53. C. Li, S. Kim, J. F. Lai et al., “Risk factors for lymph node metastasis in undifferentiated early gastric cancer,” Annals of Surgical Oncology, vol. 15, no. 3, pp. 764–769, 2008. View at Publisher · View at Google Scholar · View at Scopus
  54. T. Hirasawa, T. Gotoda, S. Miyata et al., “Incidence of lymph node metastasis and the feasibility of endoscopic resection for undifferentiated-type early gastric cancer,” Gastric Cancer, vol. 12, no. 3, pp. 148–152, 2009. View at Publisher · View at Google Scholar · View at Scopus
  55. G. P. B. Neto, E. G. dos Santos, F. C. Victer, and C. E. D. S. Carvalho, “Lymph node metastasis in early gastric cancer,” Revista do Colegio Brasileiro de Cirurgioes, vol. 41, no. 1, pp. 11–17, 2014. View at Publisher · View at Google Scholar · View at Scopus
  56. H. M. Kim, K. H. Pak, M. J. Chung et al., “Early gastric cancer of signet ring cell carcinoma is more amenable to endoscopic treatment than is early gastric cancer of poorly differentiated tubular adenocarcinoma in select tumor conditions,” Surgical Endoscopy and Other Interventional Techniques, vol. 25, no. 9, pp. 3087–3093, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. Y. Isobe, A. Nashimoto, K. Akazawa et al., “Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry,” Gastric Cancer, vol. 14, no. 4, pp. 301–316, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. J. A. Ajani, J. S. Barthel, D. J. Bentrem et al., NCCN Clinical Practice Guidelines in Oncology (NCCN GuidelinesTM). Gastric Cancer (Including Cancer in the Proximal 5 cm of the Stomach), Version 2, 2011.
  59. A. R. Novotny and C. Schuhmacher, “Predicting lymph node metastases in early gastric cancer: radical resection or organ-sparing therapy?” Gastric Cancer, vol. 11, no. 3, pp. 131–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  60. Y. Yan, L. Lu, C. Liu, W. Li, T. Liu, and W. Fu, “HER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis,” Clinics and Research in Hepatology and Gastroenterology, vol. 39, no. 1, pp. 121–126, 2015. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Boku, Y. Nakane, T. Okusa et al., “Strategy for lymphadenectomy of gastric cancer,” Surgery, vol. 105, no. 5, pp. 585–592, 1989. View at Google Scholar · View at Scopus
  62. S. Guadagni, P. I. Reed, B. J. Johnston et al., “Early gastric cancer: follow-up after gastrectomy in 159 patients,” British Journal of Surgery, vol. 80, no. 3, pp. 325–328, 1993. View at Google Scholar · View at Scopus
  63. C.-Y. Wu, J.-T. Chen, G.-H. Chen, and H.-Z. Yeh, “Lymph node metastasis in early gastric cancer: a clinicopathological analysis,” Hepato-Gastroenterology, vol. 49, no. 47, pp. 1465–1468, 2002. View at Google Scholar · View at Scopus
  64. A. Fujimoto, Y. Ishikawa, Y. Akishima-Fukasawa et al., “Significance of lymphatic invasion on regional lymph node metastasis in early gastric cancer using LYVE-1 immunohistochemical analysis,” American Journal of Clinical Pathology, vol. 127, no. 1, pp. 82–88, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. E. H. Jin, D. H. Lee, S.-A. Jung et al., “Clinicopathologic factors and molecular markers related to lymph node metastasis in early gastric cancer,” World Journal of Gastroenterology, vol. 21, no. 2, pp. 563–569, 2015. View at Publisher · View at Google Scholar · View at Scopus
  66. M. Wu, S. Semba, N. Oue, N. Ikehara, W. Yasui, and H. Yokozaki, “BRAF/K-ras mutation, microsatellite instability, and promoter hypermethylation of hMLH1/MGMT in human gastric carcinomas,” Gastric Cancer, vol. 7, no. 4, pp. 246–253, 2004. View at Publisher · View at Google Scholar · View at Scopus
  67. M. S. Hyung, S. C. Yeon, H. J. Sun et al., “Clinicopathologic characteristics and outcomes of gastric cancers with the MSI-H phenotype,” Journal of Surgical Oncology, vol. 99, no. 3, pp. 143–147, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Tamura, K. Sakata, S. Nishizuka et al., “Allelotype of adenoma and differentiated adenocarcinoma of the stomach,” Journal of Pathology, vol. 180, no. 4, pp. 371–377, 1996. View at Publisher · View at Google Scholar · View at Scopus
  69. G. Galizia, E. Lieto, M. Orditura et al., “Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery,” World Journal of Surgery, vol. 31, no. 7, pp. 1458–1468, 2007. View at Publisher · View at Google Scholar · View at Scopus
  70. C. Chen, J.-M. Yang, T.-T. Hu et al., “Prognostic role of human epidermal growth factor receptor in gastric cancer: a systematic review and meta-analysis,” Archives of Medical Research, vol. 44, no. 5, pp. 380–389, 2013. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Cao, X. Hu, Y. Zhang, and G. Huang, “Adverse prognosis of clustered-cell versus single-cell micrometastases in pN0 early gastric cancer,” Journal of Surgical Oncology, vol. 103, no. 1, pp. 53–56, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. T. Takehana, K. Kunitomo, K. Kono et al., “Status of c-erbB-2 in gastric adenocarcinoma: a comparative study of immunohistochemistry, fluorescence in situ hybridization and enzyme-linked immuno-sorbent assay,” International Journal of Cancer, vol. 98, no. 6, pp. 833–837, 2002. View at Publisher · View at Google Scholar · View at Scopus
  73. M. Tanner, M. Hollmén, T. T. Junttila et al., “Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab,” Annals of Oncology, vol. 16, no. 2, pp. 273–278, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. D. I. Park, J. W. Yun, J. H. Park et al., “HER-2/neu amplification is an independent prognostic factor in gastric cancer,” Digestive Diseases and Sciences, vol. 51, no. 8, pp. 1371–1379, 2006. View at Publisher · View at Google Scholar · View at Scopus
  75. C. Gravalos and A. Jimeno, “HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target,” Annals of Oncology, vol. 19, no. 9, pp. 1523–1529, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. G. Giuffrè, A. Ieni, V. Barresi, R. A. Caruso, and G. Tuccari, “HER2 status in unusual histological variants of gastric adenocarcinomas,” Journal of Clinical Pathology, vol. 65, no. 3, pp. 237–241, 2012. View at Publisher · View at Google Scholar · View at Scopus
  77. J. Rüschoff, W. Hanna, M. Bilous et al., “HER2 testing in gastric cancer: a practical approach,” Modern Pathology, vol. 25, no. 5, pp. 637–650, 2012. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Ieni, V. Barresi, G. Giuffrè et al., “HER2 status in advanced gastric carcinoma: a retrospective multicentric analysis from Sicily,” Oncology Letters, vol. 6, no. 6, pp. 1591–1594, 2013. View at Publisher · View at Google Scholar · View at Scopus
  79. L. Shan, J. Ying, and N. Lu, “HER2 expression and relevant clinicopathological features in gastric and gastroesophageal junction adenocarcinoma in a Chinese population,” Diagnostic Pathology, vol. 8, no. 1, article 76, 2013. View at Publisher · View at Google Scholar · View at Scopus
  80. K. Hede, “Gastric cancer: trastuzumab trial results spur search for other targets,” Journal of the National Cancer Institute, vol. 101, no. 19, pp. 1306–1307, 2009. View at Google Scholar · View at Scopus
  81. C. B. Moelans, A. N. Milne, F. H. Morsink, G. J. A. Offerhaus, and P. J. Van Diest, “Low frequency of HER2 amplification and overexpression in early onset gastric cancer,” Cellular Oncology, vol. 34, no. 2, pp. 89–95, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. M. Hofmann, O. Stoss, D. Shi et al., “Assessment of a HER2 scoring system for gastric cancer: results from a validation study,” Histopathology, vol. 52, no. 7, pp. 797–805, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. J. D. Barros-Silva, D. Leitão, L. Afonso et al., “Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients,” British Journal of Cancer, vol. 100, no. 3, pp. 487–493, 2009. View at Publisher · View at Google Scholar · View at Scopus
  84. A. H. Marx, L. Tharun, J. Muth et al., “HER-2 amplification is highly homogenous in gastric cancer,” Human Pathology, vol. 40, no. 6, pp. 769–777, 2009. View at Publisher · View at Google Scholar · View at Scopus
  85. H. Grabsch, S. Sivakumar, S. Gray, H. E. Gabbert, and W. Müller, “HER2 expression in gastric cancer: rare, heterogeneous and of no prognostic value—conclusions from 924 cases of two independent series,” Cellular Oncology, vol. 32, no. 1-2, pp. 57–65, 2010. View at Publisher · View at Google Scholar · View at Scopus
  86. G. Berx, F. Nollet, and F. van Roy, “Dysregulation of the E-cadherin/catenin complex by irreversible mutations in human carcinomas,” Cell Adhesion and Communication, vol. 6, no. 2-3, pp. 171–184, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. J. Rüschoff, M. Dietel, G. Baretton et al., “HER2 diagnostics in gastric cancer-guideline validation and development of standardized immunohistochemical testing,” Virchows Archiv, vol. 457, no. 3, pp. 299–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  88. J. M. S. Bartlett, J. Starczynski, N. Atkey et al., “HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods,” Journal of Clinical Pathology, vol. 64, no. 8, pp. 649–653, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. P. H. Cottu, J. Asselah, M. Lae et al., “Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer,” Annals of Oncology, vol. 19, no. 3, pp. 595–597, 2008. View at Google Scholar · View at Scopus
  90. M. Brunelli, E. Manfrin, G. Martignoni et al., “Genotypic intratumoral heterogeneity in breast carcinoma with HER2/fieif emplification wvaluation according to ASCO/CAP criteria,” American Journal of Clinical Pathology, vol. 131, no. 5, pp. 678–682, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. L. Albarello, L. Pecciarini, and C. Doglioni, “HER2 testing in gastric cancer,” Advances in Anatomic Pathology, vol. 18, no. 1, pp. 53–59, 2011. View at Publisher · View at Google Scholar · View at Scopus
  92. M. A. Kim, H.-J. Lee, H.-K. Yang, Y.-J. Bang, and W. H. Kim, “Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma,” Histopathology, vol. 59, no. 5, pp. 822–831, 2011. View at Publisher · View at Google Scholar · View at Scopus
  93. B. Yan, E. X. Yau, S. N. Choo et al., “Dual-colour HER2/Chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samples,” Journal of Clinical Pathology, vol. 64, no. 10, pp. 880–883, 2011. View at Publisher · View at Google Scholar · View at Scopus
  94. J. Yang, H. Luo, Y. Li et al., “Intratumoral heterogeneity determines discordant results of diagnostic tests for human epidermal growth factor receptor (HER) 2 in gastric cancer specimens,” Cell Biochemistry and Biophysics, vol. 62, no. 1, pp. 221–228, 2012. View at Publisher · View at Google Scholar · View at Scopus
  95. M. Pirrelli, M. L. Caruso, M. Di Maggio, R. Armentano, and A. M. Valentini, “Are biopsy specimens predictive of HER2 status in gastric cancer patients?” Digestive Diseases and Sciences, vol. 58, no. 2, pp. 397–404, 2013. View at Publisher · View at Google Scholar · View at Scopus
  96. T. Wang, E. T. Hsieh, P. Henry, W. Hanna, C. J. Streutker, and A. Grin, “Matched biopsy and resection specimens of gastric and gastroesophageal adenocarcinoma show high concordance in HER2 status,” Human Pathology, vol. 45, no. 5, pp. 970–975, 2014. View at Publisher · View at Google Scholar · View at Scopus
  97. S.-C. Huang, K.-F. Ng, S.-E. Lee, K.-H. Chen, T.-S. Yeh, and T.-C. Chen, “HER2 testing in paired biopsy and excision specimens of gastric cancer: the reliability of the scoring system and the clinicopathological factors relevant to discordance,” Gastric Cancer, 2014. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Asioli, F. Maletta, L. V. di Cantogno et al., “Approaching heterogeneity of human epidermal growth factor receptor 2 in surgical specimens of gastric cancer,” Human Pathology, vol. 43, no. 11, pp. 2070–2079, 2012. View at Publisher · View at Google Scholar · View at Scopus
  99. J. H. Kim, M. A. Kim, H. S. Lee, and W. H. Kim, “Comparative analysis of protein expressions in primary and metastatic gastric carcinomas,” Human Pathology, vol. 40, no. 3, pp. 314–322, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. S. J. Aitken, J. S. Thomas, S. P. Langdon, D. J. Harrison, and D. Faratian, “Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases,” Annals of Oncology, vol. 21, no. 6, pp. 1254–1261, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. C. Bozzetti, F. V. Negri, C. A. Lagrasta et al., “Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma,” British Journal of Cancer, vol. 104, no. 9, pp. 1372–1376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  102. A. Chan, A. Morey, B. Brown, D. Hastrich, P. Willsher, and D. Ingram, “A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease,” BMC Cancer, vol. 12, article 555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  103. M. V. Dieci, E. Barbieri, F. Piacentini et al., “Discordance in receptor status between primary and recurrent breast cancer has a prognostic impact: a single-institution analysis,” Annals of Oncology, vol. 24, no. 1, Article ID mds248, pp. 101–108, 2013. View at Publisher · View at Google Scholar · View at Scopus
  104. M. Kochi, M. Fujii, S. Masuda et al., “Differing deregulation of HER2 in primary gastric cancer and synchronous related metastatic lymph nodes,” Diagnostic Pathology, vol. 8, no. 1, article 191, 2013. View at Publisher · View at Google Scholar · View at Scopus
  105. G. Aurilio, D. Disalvatore, G. Pruneri et al., “A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases,” European Journal of Cancer, vol. 50, no. 2, pp. 277–289, 2014. View at Publisher · View at Google Scholar · View at Scopus
  106. A. Ieni, V. Barresi, G. Giuffrè et al., “Letter to the Editor regarding the paper by Aurilio et al., a meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases,” European Journal of Cancer, vol. 50, no. 5, pp. 1035–1037, 2014. View at Publisher · View at Google Scholar
  107. A. Ieni, V. Barresi, R. Caltabiano et al., “Discordance rate of HER2 status in primary breast carcinomas versus synchronous axillary lymph node metastases: a multicenter retrospective investigation,” OncoTargets and Therapy, vol. 7, pp. 1267–1272, 2014. View at Publisher · View at Google Scholar · View at Scopus
  108. A. Ieni, V. Barresi, R. Caltabiano et al., “Discordance rate of HER2 status in primary gastric carcinomas and synchronous lymph node metastases: a multicenter retrospective analysis,” International Journal of Molecular Sciences, vol. 15, no. 12, pp. 22331–22341, 2014. View at Publisher · View at Google Scholar · View at Scopus
  109. D. Tsapralis, I. Panayiotides, G. Peros, T. Liakakos, and E. Karamitopoulou, “Human epidermal growth factor receptor-2 gene amplification in gastric cancer using tissue microarray technology,” World Journal of Gastroenterology, vol. 18, no. 2, pp. 150–155, 2012. View at Publisher · View at Google Scholar · View at Scopus
  110. E. Yoon Cho, K. Park, I. Do et al., “Heterogeneity of ERBB2 in gastric carcinomas: a study of tissue microarray and matched primary and metastatic carcinomas,” Modern Pathology, vol. 26, no. 5, pp. 677–684, 2013. View at Publisher · View at Google Scholar · View at Scopus
  111. M. Fassan, M. Pizzi, S. Realdon et al., “The HER2-miR125a5p/miR125b loop in gastric and esophageal carcinogenesis,” Human Pathology, vol. 44, no. 9, pp. 1804–1810, 2013. View at Publisher · View at Google Scholar · View at Scopus
  112. Y. Geng, X. Chen, J. Qiu et al., “Human epidermal growth factor receptor-2 expression in primary and metastatic gastric cancer,” International Journal of Clinical Oncology, vol. 19, no. 2, pp. 303–311, 2014. View at Publisher · View at Google Scholar · View at Scopus
  113. Z. Peng, J. Zou, X. Zhang et al., “HER2 discordance between paired primary gastric cancer and metastasis: a meta-analysis,” Chinese Journal of Cancer Research, vol. 27, no. 2, pp. 163–171, 2015. View at Google Scholar
  114. P. Tan, “Gastric cancer—a convergence of genomic heterogeneity,” Translational Gastrointestinal Cancer, vol. 4, no. 2, pp. 118–122, 2015. View at Google Scholar
  115. H.-Z. Dang, Y. Yu, and S.-C. Jiao, “Prognosis of HER2 over-expressing gastric cancer patients with liver metastasis,” World Journal of Gastroenterology, vol. 18, no. 19, pp. 2402–2407, 2012. View at Publisher · View at Google Scholar · View at Scopus
  116. C. Gómez-Martin, E. Garralda, M. J. Echarri et al., “HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer,” Journal of Clinical Pathology, vol. 65, no. 8, pp. 751–757, 2012. View at Publisher · View at Google Scholar · View at Scopus
  117. Y. Y. Janjigian, D. Werner, C. Pauligk et al., “Prognosis of metastatic gastric and gastroesophageal junction cancer by HER2 status: a European and USA International collaborative analysis,” Annals of Oncology, vol. 23, no. 10, pp. 2656–2662, 2012. View at Publisher · View at Google Scholar · View at Scopus
  118. J. T. Jørgensen and M. Hersom, “HER2 as a prognostic marker in gastric cancer—a systematic analysis of data from the literature,” Journal of Cancer, vol. 3, no. 1, pp. 137–144, 2012. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Kataoka, H. Okabe, A. Yoshizawa et al., “HER2 expression and its clinicopathological features in resectable gastric cancer,” Gastric Cancer, vol. 16, no. 1, pp. 84–93, 2013. View at Publisher · View at Google Scholar · View at Scopus
  120. J. W. Kim, S.-A. Im, M. Kim et al., “The prognostic significance of HER2 positivity for advanced gastric cancer patients undergoing first-line modified FOLFOX-6 regimen,” Anticancer Research, vol. 32, no. 4, pp. 1547–1553, 2012. View at Google Scholar · View at Scopus
  121. K. Shitara, Y. Yatabe, K. Matsuo et al., “Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment,” Gastric Cancer, vol. 16, no. 2, pp. 261–267, 2013. View at Publisher · View at Google Scholar · View at Scopus
  122. H. Allgayer, R. Babic, K. U. Gruetzner, A. Tarabichi, F. W. Schildberg, and M. M. Heiss, “c-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor-associated protease systems,” Journal of Clinical Oncology, vol. 18, no. 11, pp. 2201–2209, 2000. View at Google Scholar · View at Scopus
  123. N. Fuse, Y. Kuboki, T. Kuwata et al., “Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients,” Gastric Cancer, 2015. View at Publisher · View at Google Scholar · View at Scopus
  124. J. Matsubara, YasuhideYamada, Y. Hirashima et al., “Impact of insulin-like growth factor type 1 receptor, epidermal growth factor receptor, and HER2 expressions on outcomes of patients with gastric cancer,” Clinical Cancer Research, vol. 14, no. 10, pp. 3022–3029, 2008. View at Publisher · View at Google Scholar · View at Scopus